Secins – Cytohesin Inhibitors
Compounds for the inhibition of EGFR-signalling.
Invention: Pharmacological inhibition of cell proliferation, adhesion and migration is pivotal in the treatment of a wide variety of cancers. A prominent protein involved in these processes and associated with the onset of cancer in humans is the EGF receptor. It was surprisingly found by the inventors that cytohesins are a pathophysiologically relevant class of cytoplasmatic EGFR activators. Therefore, they are an attractive target for the modulation of different disease-relevant signal transduction pathways. A correlation of cytohesin expression with EGFR-signalling could already be shown for human lung adenocarcinoma. By cytohesin inhibition, therapeutic interventions may be possible in the future. The present invention discloses small molecules which combine a highly selective inhibitory effect on cytohesins with cell permeability and low toxicity.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Caution, hot surface!
An international research team from the University of Jena and the Helmholtz Institute Jena are demystifying the mechanisms by which high-intensity laser pulses produce plasma on the surface of solids….
Exploring the Asteroid Apophis With Small Satellites
In five years’ time, a large asteroid will fly very close to Earth – a unique opportunity to study it. Concepts for a national German small satellite mission are being…
First model of the brain’s information highways developed
Our human brain is not only bigger and contains more neurons than the brains of other species, but it is also connected in a special pattern: Thick bundles of neurons…
